Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Hemicolectomy | Research

Chemotherapy in the treatment of different histological types of appendiceal cancers: a SEER based study

Authors: Gang Wang, Qiken Li, Weiping Chen

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Due to its rarity and high heterogeneity, neither established guidelines nor prospective data are currently available for using chemotherapy in the treatment of appendiceal cancer. This study was to determine the use of chemotherapy and its potential associations with survival in patients with different histological types of the cancer.

Methods

Patients with histologically different appendiceal cancers diagnosed during 1998–2016 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. The role and effect of chemotherapy were examined in the treatment of the disease. The Kaplan-Meier method was applied to construct survival curves and significance was examined by Log-rank test. Cox proportional hazard models were used to analyze the impact of chemotherapy and other variables on survival in these patients.

Results

A total of 8733 appendiceal cancer patients were identified from the database. Chemotherapy was administrated at highly variable rates in different histological types of appendiceal cancer. As high as 64.0% signet ring cell carcinoma (SRCC), 46.4% of mucinous adenocarcinomas (MAC), 40.6% of non-mucinous adenocarcinoma (NMAC) and 43.9% of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) were treated with chemotherapy, whereas only 14.7% of goblet cell carcinoma (GCC), 5% neuroendocrine tumors (NETs) and 1.6% carcinomas (NEC) received chemotherapy. In all patients combined, chemotherapy significantly improved overall survival during the entire study period and cancer-specific survival was improved during in cases from 2012–2016. Further multivariate analysis showed that both cancer-specific and overall survival was significantly improved with chemotherapy in patients with MAC, NMAC and SRCC, but not for patients with GCC, MiNENs, NETs and NECs. Number (> 12) of lymph node sampled was associated with survival of patients with most histological types of cancer under study. Other prognostic factors related to individual histological types were identified.

Conclusions

Chemotherapy is administrated at highly variable rates in different histological types of appendiceal cancer. Efficacy of chemotherapy in the treatment of these cancers has been improved in recent years and is significantly associated with better survival for patients with NMAC, MAC, and SRCC. Adequate lymph node sampling may result in a survival benefit for most of these patients.

Available only for authorised users

Marmor S, Portschy PR, Tuttle TM, Virnig BA. The rise in appendiceal cancer incidence: 2000-2009. J Gastrointest Surg. 2015;19(4):743–50. https://doi.org/10.1007/s11605-014-2726-7.CrossRefPubMed

Zheng M, Li T, Li Y, Zhang T, Zhang L, Ma W, et al. Survival profile and prognostic factors for Appendiceal mixed neuroendocrine non-neuroendocrine neoplasms: a SEER population-based study. Front Oncol. 2020;10:1660. https://doi.org/10.3389/fonc.2020.01660.CrossRefPubMedPubMedCentral

Kelly KJ. Management of Appendix Cancer. Clin Colon Rectal Surg. 2015;28(4):247–55. https://doi.org/10.1055/s-0035-1564433.CrossRefPubMedPubMedCentral

Tejani MA, ter Veer A, Milne D, Ottesen R, Bekaii-Saab T, Benson AB 3rd, et al. Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN oncology outcomes database for colorectal cancer. J Natl Compr Cancer Netw. 2014;12(8):1123–30. https://doi.org/10.6004/jnccn.2014.0109.CrossRef

Asare EA, Compton CC, Hanna NN, Kosinski LA, Washington MK, Kakar S, et al. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: analysis of the National Cancer Data Base. Cancer. 2016;122(2):213–21. https://doi.org/10.1002/cncr.29744.CrossRefPubMed

Lu P, Fields AC, Meyerhardt JA, Davids JS, Shabat G, Bleday R, et al. Systemic chemotherapy and survival in patients with metastatic low-grade appendiceal mucinous adenocarcinoma. J Surg Oncol. 2019;120(3):446–51. https://doi.org/10.1002/jso.25599.CrossRefPubMedPubMedCentral

Shapiro JF, Chase JL, Wolff RA, Lambert LA, Mansfield PF, Overman MJ, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010;116(2):316–22. https://doi.org/10.1002/cncr.24715.CrossRefPubMed

Lieu CH, Lambert LA, Wolff RA, Eng C, Zhang N, Wen S, et al. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012;23(3):652–8. https://doi.org/10.1093/annonc/mdr279.CrossRefPubMed

Uemura M, Qiao W, Fournier K, Morris J, Mansfield P, Eng C, et al. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. BMC Cancer. 2017;17(1):331. https://doi.org/10.1186/s12885-017-3327-0.CrossRefPubMedPubMedCentral

10.

Barrak D, Desale S, Yoon JJ, Dugan MM, Kodavanti PP, Sampah ME, et al. Appendiceal tumors with glandular and neuroendocrine features exhibiting peritoneal metastases - Critical evaluation of outcome following cytoreductive surgery with perioperative chemotherapy. Eur J Surg Oncol. 2021;47(6):1278-85. https://doi.org/10.1016/j.ejso.2021.01.010.

11.

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Data, 9 Registries, Nov 2019 Sub (1975–2017) - Linked To County Attributes - Time Dependent (1990–2017) Income/Rurality, 1969–2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2020, based on the November 2019 submission.

12.

Kolla BC, Petersen A, Chengappa M, Gummadi T, Ganesan C, Gaertner WB, et al. Impact of adjuvant chemotherapy on outcomes in appendiceal cancer. Cancer Med. 2020;9(10):3400–6. https://doi.org/10.1002/cam4.3009.CrossRefPubMedPubMedCentral

13.

Munoz-Zuluaga CA, King MC, Ledakis P, Gushchin V, Sittig M, Nieroda C, et al. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin. Eur J Surg Oncol. 2019;45(9):1598–606. https://doi.org/10.1016/j.ejso.2019.05.008.CrossRefPubMed

14.

Akce M, Zakka K, Penley M, Jiang R, Khalil L, Alese OB, et al. Impact of high-risk features for stage II adenocarcinoma of the appendix. Cancer Treat Res Commun. 2021;27:100329. https://doi.org/10.1016/j.ctarc.2021.100329.CrossRefPubMed

15.

Benedix F, Reimer A, Gastinger I, Mroczkowski P, Lippert H, Kube R. Study group Colon/rectum carcinoma primary T: primary appendiceal carcinoma--epidemiology, surgery and survival: results of a German multi-center study. Eur J Surg Oncol. 2010;36(8):763–71. https://doi.org/10.1016/j.ejso.2010.05.025.CrossRefPubMed

16.

Pawa N, Clift AK, Osmani H, Drymousis P, Cichocki A, Flora R, et al. Surgical Management of Patients with neuroendocrine neoplasms of the appendix: appendectomy or more. Neuroendocrinology. 2018;106(3):242–51. https://doi.org/10.1159/000478742.CrossRefPubMed

17.

Emre A, Akbulut S, Bozdag Z, Yilmaz M, Kanlioz M, Emre R, et al. Routine histopathologic examination of appendectomy specimens: retrospective analysis of 1255 patients. Int Surg. 2013;98(4):354–62. https://doi.org/10.9738/INTSURG-D-13-00098.1.CrossRefPubMedPubMedCentral

18.

Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, et al. ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology. 2012;95(2):135–56. https://doi.org/10.1159/000335629.CrossRefPubMed

19.

Sinno SAJ, Jurdi NMH. Goblet cell tumors of the appendix: a review. Ann Diagn Pathol. 2019;43:151401. https://doi.org/10.1016/j.anndiagpath.2019.151401.CrossRefPubMed

20.

Wen KW, Hale G, Shafizadeh N, Hosseini M, Huang A, Kakar S. Appendiceal goblet cell carcinoid: common errors in staging and clinical interpretation with a proposal for an improved terminology. Hum Pathol. 2017;65:187–93. https://doi.org/10.1016/j.humpath.2017.05.012.CrossRefPubMed

21.

Pham TH, Wolff B, Abraham SC, Drelichman E. Surgical and chemotherapy treatment outcomes of goblet cell carcinoid: a tertiary cancer center experience. Ann Surg Oncol. 2006;13(3):370–6. https://doi.org/10.1245/ASO.2006.02.016.CrossRefPubMed

22.

Lamarca A, Nonaka D, Lopez Escola C, Hubner RA, O'Dwyer S, Chakrabarty B, et al. Appendiceal goblet cell carcinoids: management considerations from a reference peritoneal tumour service Centre and ENETS Centre of excellence. Neuroendocrinology. 2016;103(5):500–17. https://doi.org/10.1159/000440725.CrossRefPubMed

23.

Shenoy S. Goblet cell carcinoids of the appendix: tumor biology, mutations and management strategies. World J Gastrointest Surg. 2016;8(10):660–9. https://doi.org/10.4240/wjgs.v8.i10.660.CrossRefPubMedPubMedCentral

24.

Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010;39(6):753–66. https://doi.org/10.1097/MPA.0b013e3181ebb2a5.CrossRefPubMed

25.

AlMasri S, Nassour I, Kowalsky SJ, Hrebinko K, Singhi AD, Lee KK, et al. The role of adjuvant chemotherapy in non-metastatic goblet cell carcinoid of the appendix: an 11-year experience from the National Cancer Database. Ann Surg Oncol. 2020.

26.

Zakka K, Williamson S, Jiang R, Reid MD, Alese OB, Shaib WL, et al. Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix? Surg Oncol. 2021;36:120–9. https://doi.org/10.1016/j.suronc.2020.12.003.CrossRefPubMed

27.

Brathwaite S, Rock J, Yearsley MM, Bekaii-Saab T, Wei L, Frankel WL, et al. Mixed Adeno-neuroendocrine Carcinoma: An Aggressive Clinical Entity. Ann Surg Oncol. 2016;23(7):2281–6. https://doi.org/10.1245/s10434-016-5179-2.CrossRefPubMedPubMedCentral

28.

Shannon AB, Goldberg D, Song Y, Paulson EC, Roses RE, Fraker DL, et al. Predictors of lymph node metastases in patients with mucinous appendiceal adenocarcinoma. J Surg Oncol. 2020;122(3):399–406. https://doi.org/10.1002/jso.25963.CrossRefPubMed

29.

Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124(7):979–94.CrossRef

30.

Sarli L, Bader G, Iusco D, Salvemini C, Mauro DD, Mazzeo A, et al. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer. 2005;41(2):272–9. https://doi.org/10.1016/j.ejca.2004.10.010.CrossRefPubMed

31.

Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007;99(6):433–41. https://doi.org/10.1093/jnci/djk092.CrossRefPubMed

Title: Chemotherapy in the treatment of different histological types of appendiceal cancers: a SEER based study
Authors: Gang Wang
Qiken Li
Weiping Chen
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Hemicolectomy
Hemicolectomy
Cytostatic Therapy
Neuroendocrine Tumor
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08502-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Correction to: Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study

Overexpression of TNFα induces senescence, autophagy and mitochondrial dysfunctions in melanoma cells

Depression, anxiety, fatigue, and quality of life in a large sample of patients suffering from head and neck cancer in comparison with the general population

Reference-free transcriptome signatures for prostate cancer prognosis

TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma

Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer